PHA-665752

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C32H34Cl2N4O4S
Molecular Weight	641.608
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=C(C(=O)N2CCC[C@@H]2CN3CCCC3)C(C)=C(N1)\C=C4/C(=O)NC5=C4C=C(C=C5)S(=O)(=O)CC6=C(Cl)C=CC=C6Cl

InChI

InChIKey=OYONTEXKYJZFHA-SSHUPFPWSA-N

InChI=1S/C32H34Cl2N4O4S/c1-19-29(35-20(2)30(19)32(40)38-14-6-7-21(38)17-37-12-3-4-13-37)16-24-23-15-22(10-11-28(23)36-31(24)39)43(41,42)18-25-26(33)8-5-9-27(25)34/h5,8-11,15-16,21,35H,3-4,6-7,12-14,17-18H2,1-2H3,(H,36,39)/b24-16-/t21-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C32H34Cl2N4O4S
Molecular Weight	641.608
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	1
Optical Activity	UNSPECIFIED

Approval Year

Targets

Primary Target	Pharmacology	Potency
Hepatocyte growth factor receptor 56 Target ID: CHEMBL3717 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14612533	Inhibitor 8504	0.009 µM [IC50]
Macrophage-stimulating protein receptor 4 Target ID: CHEMBL2689 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14612533	Inhibitor 8504	0.068 µM [IC50]
Vascular endothelial growth factor receptor 2 112 Target ID: CHEMBL279 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14612533	Inhibitor 8504	0.2 µM [IC50]
Tyrosine-protein kinase ABL 29 Target ID: CHEMBL1862 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14612533	Inhibitor 8504	1.4 µM [IC50]
Fibroblast growth factor receptor 1 46 Target ID: CHEMBL3650 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14612533	Inhibitor 8504	3.0 µM [IC50]

PubMed

Title	Date	PubMed
Ochratoxin A activates opposing c-MET/PI3K/Akt and MAPK/ERK 1-2 pathways in human proximal tubule HK-2 cells.	2015-08	25002221
Comprehensive analysis of kinase inhibitor selectivity.	2011-10-30	22037378
Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).	2011-09-22	21812414
Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.	2011-02-01	21266357
Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer.	2011-02-01	21106725
HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma.	2011-01	20661229
Involvement of c-Met- and phosphatidylinositol 3-kinase dependent pathways in arsenite-induced downregulation of catalase in hepatoma cells.	2011	22040890
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.	2010-11-24	21095574
A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.	2003-11-01	14612533

Substance Class	Chemical Created by `admin` on `Mon Mar 31 23:18:10 GMT 2025` Edited by `admin` on `Mon Mar 31 23:18:10 GMT 2025`
Record UNII	0VXU5T5R3J
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PHA-665752

Common Name

English

2H-INDOL-2-ONE, 5-(((2,6-DICHLOROPHENYL)METHYL)SULFONYL)-3-((3,5-DIMETHYL-4-(((2R)-2-(1-PYRROLIDINYLMETHYL)-1-PYRROLIDINYL)CARBONYL)-1H-PYRROL-2-YL)METHYLENE)-1,3-DIHYDRO-, (3Z)-

Preferred Name

English

PHA 665752 [WHO-DD]

Common Name

English

Code System Code Type Description

CAS

477575-56-7

Created by admin on Mon Mar 31 23:18:10 GMT 2025 , Edited by admin on Mon Mar 31 23:18:10 GMT 2025

PRIMARY

EPA CompTox

DTXSID30197270

Created by admin on Mon Mar 31 23:18:10 GMT 2025 , Edited by admin on Mon Mar 31 23:18:10 GMT 2025

PRIMARY

PUBCHEM

10461815

Created by admin on Mon Mar 31 23:18:10 GMT 2025 , Edited by admin on Mon Mar 31 23:18:10 GMT 2025

PRIMARY

FDA UNII

0VXU5T5R3J

Created by admin on Mon Mar 31 23:18:10 GMT 2025 , Edited by admin on Mon Mar 31 23:18:10 GMT 2025

PRIMARY

Related Record Type Details


					0VXU5T5R3J

PHA-665752

ACTIVE MOIETY